Efficacy and Safety of Ningmitai Capsule Alone or Combined With Celecoxib in the Treatment of CP/CPPS
CompletedPhase 4NCT06159114
View the official record on ClinicalTrials.gov Recruiting status changes often. Contact the study team listed on ClinicalTrials.gov, and talk to your doctor before joining a study.
This study has no listed site in Canada in this snapshot. It is included as part of the worldwide chronic pain corpus.
Brief summary (from the registry)
Clinical trial title：Efficacy and safety of Ningmitai capsule alone or combined with celecoxib in the treatment of Chronic Prostatitis/Chronic Pelvic Pain Syndrome (CP/CPPS): A prospective, randomized, double-blind, multicenter clinical study Principal investigator：Zhou Huiliang Main research units：The First Affiliated Hospital of Fujian Medical University Clinical trial start and end dates：2023/07/01-2025/12/31 Objective: To evaluate whether Ningmitai capsule(NMT) alone or combined with Celecoxib for 6 weeks is more effective than Celecoxib in improving pain symptoms of CP/CPPS patients. Study type: Interventional study Total sample size:240 Inclusion criteria: 1. Age: male patients aged 18-60 years; 2. Long-term and repeated pelvic discomfort or pain (NIH-CPSI pain score ≥ 4 points), lasting more than 3 months, may be accompanied by different degrees of urination symptoms and sexual dysfunction; 3. Negative bacterial in urine before and after prostate massage; 4. Voluntarily participate in the trial. Exclusion criteria: 1. Utilize any drugs for the treatment of chronic prostatitis in the past 2 weeks; 2. Patients who have received prostate surgery and treatment; 3. Urine WBC ≥ 5/HP, urinary system infection within 12 months, and effective antibiotic treatment in the early stage; 4. Pelvic pain and voiding dysfunction caused by non-prostatitis factors. 5. Suffering from serious primary cardiovascular disease, liver disease, kidney disease, hematological disease, lung disease or other serious diseases such as tumors or AIDS; 6. Significant adverse events in clinical or laboratory examination. 7. Allergic to the components of the test drugs or sulfa; 8. Previous active peptic ulcer / bleeding; 9. A birth plan within the past 8 months; 10. Legally disabled patients or psychiatric patients; 11. Suspected or confirmed alcohol or drug abuse, or other conditions that reduce the possibility of enrollment； 12. Participating in other clinical trials; 13. Considered unsuitabl…
Study details
- Official title
- Efficacy and Safety of Ningmitai Capsule Alone or Combined With Celecoxib in the Treatment of Chronic Prostatitis/Chronic Pelvic Pain Syndrome (CP/CPPS): A Prospective, Randomized, Double-blind, Multicenter Clinical Study
- Conditions
- Interventions
- Drug: Ningmitai capsule
- Drug: Celecoxib capsule
- Drug: Ningmitai placebo
- Drug: Celecoxib placebo
- Sponsor
- Xintian Pharmaceutical
- Start date
- 2023-12-19
- Primary completion
- 2025-01-31
- Sex
- Male
- Age range
- from 18 Years to 60 Years
- Results posted
- No results posted in this snapshot
- Countries
- China
- Total sites listed
- 1
Eligibility criteria
Show eligibility criteria (verbatim from the registry)
Inclusion Criteria: 1. Age: male patients aged 18-60 years; 2. Long-term and repeated pelvic discomfort or pain (NIH-CPSI pain score ≥ 4 points), lasting more than 3 months, may be accompanied by different degrees of urination symptoms and sexual dysfunction; 3. Negative bacterial in urine before and after prostate massage; 4. Voluntarily participate in the trial and agree to sign an informed consent form. Exclusion Criteria: 1. Use any non-steroidal anti-inflammatory drugs，α receptor blockers，antibiotics, PDE5 inhibitors or other traditional Chinese medicines or botanicals for the treatment of prostatitis in the past 2 weeks; those who are using drugs for the treatment of prostatitis need to stop the drug for 2 weeks before the clinical trial; 2. Patients who have received prostate surgery and treatment such as TURP, TUIP, open prostatectomy, biofeedback therapy, hyperthermia, ablation, prostate cryotherapy, transperineal extracorporeal shock wave therapy, prostate injection therapy, transurethral prostate perfusion therapy, or bladder surgery such as bladder neck incision; 3. Urine WBC ≥ 5 /HP, urinary system infection within 3 months; 4. Pelvic pain and voiding dysfunction caused by non-prostatitis factors, such as benign prostatic hyperplasia, diseases of testis, epididymis and spermatic cord, overactive bladder, neurogenic bladder, interstitial cystitis, glandular cystitis, sexually transmitted diseases, bladder tumor, prostate cancer, anorectal disease, lumbar disease, central and peripheral neuropathy; 5. Suffering from serious primary cardiovascular disease, liver disease, kidney disease, hematological disease, lung disease or other serious diseases such as tumors or AIDS; 6. Significant adverse events in clinical or laboratory examination indicators, such as ALT and AST ≥ 1.5 times the upper limit of reference value, creatinine (SCR) \> the upper limit of reference value; 7. Allergic to the components of the test drugs or sulfa; 8. Previous active peptic ulcer / bleeding; 9. A birth plan within the past 8 months; 10. Legally disabled patients (blind, deaf, mute, intellectual disability, etc.), psychiatric patients; 11. Suspected or confirmed alcohol or drug abuse, or other conditions that reduce the possibility of enrollment or complicate enrollment according to the judgment of the investigator, such as frequent changes in the working environment that are likely to cause loss to follow-up; 12. Participating in other clinical trials; 13. Considered…
Source: ClinicalTrials.gov (US National Library of Medicine), snapshot October 2026. Check the registry for current recruiting status. Record: https://clinicaltrials.gov/study/NCT06159114